FinscoFinsco

Amphastar Pharmaceuticals (US.AMPH)

Capital Allocation Audit · Period: 2011 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.AMPH · YoY: 2026 H1 vs 2025 H1

MetricValueYoY
FCF Conversion81.7%↑
ROE4.8%↓
Cash Conversion269.7%↑
D/E Ratio0.90→
Gross Margin46.1%↓
US.AMPH (Amphastar Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1


Metric            Value  YoY
----------------------------
FCF Conversion    81.7%    ↑
ROE                4.8%    ↓
Cash Conversion  269.7%    ↑
D/E Ratio          0.90    →
Gross Margin      46.1%    ↓
Key Metrics
US.AMPH (Amphastar Pharmaceuticals) | YoY: 2026 H1 vs 2025 H1
Metric Value YoY
----------------------------
FCF Conversion 81.7% ↑
ROE 4.8% ↓
Cash Conversion 269.7% ↑
D/E Ratio 0.90 →
Gross Margin 46.1% ↓

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-CAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesMicron TechnologySanDiskSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies